{
    "name": "dalfampridine",
    "comment": "Rx",
    "other_names": [
        "Ampyra"
    ],
    "classes": [
        "Multiple Sclerosis Treatments",
        "Potassium Channel Blockers",
        "Cholinergic Agonists"
    ],
    "source": "https://reference.medscape.com/drug/ampyra-dalfampridine-999450",
    "pregnancy": {
        "common": [
            "There are no adequate data on developmental risk associated with use in pregnant women"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Administration to animals during pregnancy and lactation resulted in decreased offspring viability and growth at clinically relevant doses"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Moderate or severe renal impairment (CrCl ≤50 mL/min)",
                "History of seizure"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Seizures reported; permanently discontinue if seizure occurs; majority of seizures happened within days to weeks after starting the recommended dose and occurred in patients having no history of seizures",
                "Age-related decreases in renal function, and mild renal impairment is common after age 50 yr, plasma levels may approach those seen at dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures; even when serum creatinine is normal, renal function should be assessed by estimating creatinine clearance",
                "Do not take with other forms of 4-aminopyridine (4-AP, fampridine) to avoid adverse reaction due to the same active ingredient",
                "Estimate CrCl before initiating (see Contraindications and Renal Impairment)",
                "Do not double dose or take extra if dose missed",
                "Anaphylaxis and severe allergic reactions; signs and symptoms have included respiratory compromise, urticaria, and angioedema of the throat and or tongue; discontinue immediately and do not restart (see Contraindications)",
                "UTIs reported more frequently in clinical trials vs. placebo"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "trilaciclib",
            "description": {
                "common": "trilaciclib will increase the level or effect of dalfampridine by  Other (see comment). Avoid or Use Alternate Drug.  Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with dalfampridine. Consider potential benefits of trilaciclib against risk of seizures with increased dalfampridine blood levels."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dolutegravir",
            "description": {
                "common": "dolutegravir will increase the level or effect of dalfampridine by  Other (see comment). Modify Therapy/Monitor Closely. dolutegravir inhibits OCT2 and multidrug and toxin extrusion transporter 1"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "metformin, dalfampridine.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment:    Metformin and dalfampridine are organic cation transporter 2 (OCT2) substrates; both drugs may compete for renal tubular uptake and could potentially increase systemic exposure of either drug when administered concomitantly."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Urinary tract infection",
            "percent": "12"
        },
        {
            "name": "Insomnia",
            "percent": "4.6"
        },
        {
            "name": "Dizziness",
            "percent": "1000"
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "Back pain",
            "percent": null
        },
        {
            "name": "Balance disorder",
            "percent": null
        },
        {
            "name": "Multiple sclerosis relapse",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Nasopharyngitis",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Dyspepsia",
            "percent": null
        },
        {
            "name": "Pharyngolaryngeal pain",
            "percent": null
        },
        {
            "name": "Dose",
            "percent": null
        },
        {
            "name": "related increased risk of seizures",
            "percent": null
        },
        {
            "name": "Seizures",
            "percent": null
        },
        {
            "name": "per",
            "percent": null
        },
        {
            "name": "patient",
            "percent": null
        },
        {
            "name": "years of use",
            "percent": null
        },
        {
            "name": "which is comparable to the rate of seizures seen in the overall MS population",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "vertigo",
            "percent": null
        }
    ]
}